From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2
Are you struggling with the complexities of cell and gene therapy manufacturing and wondering how automation and digital solutions can truly make these life-saving therapies accessible to more people?
From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1
Cell and gene therapies have opened the doors to personalized medicine, but manufacturing these complex therapies is filled with hidden process risks that can compromise efficacy and patient access.
How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?
How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1
What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?
How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2
T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.
How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1
Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.
DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity – Part 2
What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?
DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity – Part 1
Why hasn’t DMSO been dethroned—and what’s finally threatening its reign?
Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes – Part 2
For decades, contract development and manufacturing organizations (CDMOs) have grown by building bigger stainless-steel facilities and squeezing ever-tighter margins.
Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes – Part 1
What if continuous microbial manufacturing wasn’t a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?